Automation is key to siRNA

The potential of gene editing as a therapeutic has come to fruition in the past several years, as clinical data from various studies has shown very positive results.

Plasmid DNA products are one of the most common non-viral vectors, frequently used in both in vivo and ex vivo gene therapies. As a result, they can be utilised as drug substance (DS)/drug product (DP), intermediate or starting material.

From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in research due to their role as intercellular messengers in health and disease. While their translational applications appear unlimited, the study of exosomes is challenged by their small size and heterogenous nature. In this webinar you will learn more about the common methods for exosome research and the proficient tools that Miltenyi Biotec offers to isolate and analyze exosomes. Join to connect with us and hear more.

The development of novel biotherapeutics is an essential element in generating the power to cure the incurable. With recent advances in cell and molecular biology, cell therapy has emerged as an effective means to treat a host of biological disorders. However, challenges remain for the clinical and commercial manufacturing of these advanced therapy products. Join us for this GEN webinar where we will discuss the manufacturing challenges that many researchers face as they begin to scale-out and scale-up biotherapy production. Moreover, we will discuss how the latest solutions from Corning Life Sciences can streamline bioproduction workflows and ease those cell and regenerative therapy manufacturing woes.